Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084444 | 0.86 | LMNA (0.56) | LMNANAAATSHRPTPN1CDC25B | |
| SCHEMBL22569916 | 0.86 | LMNA (0.56) | LMNANAAATSHRPTPN1CDC25B | |
| SCHEMBL18227616 | 0.82 | LMNA (0.43) | LMNANAAAMEN1KMT2APDE4D | |
| SCHEMBL18227562 | 0.82 | LMNA (0.43) | LMNANAAAMEN1KMT2APDE4D | |
| SCHEMBL1459289 | 0.78 | LMNA (0.49) | LMNANAAAMEN1KMT2APDE4D | |
| SCHEMBL1459291 | 0.78 | LMNA (0.49) | LMNANAAAMEN1KMT2APDE4D | |
| SCHEMBL19666233 | 0.76 | MEN1 (0.46) | LMNANAAAMEN1KMT2APDE4D | |
| SCHEMBL19666079 | 0.76 | MEN1 (0.46) | LMNANAAAMEN1KMT2APDE4D | |
| SCHEMBL16464737 | 0.74 | LMNA (0.46) | LMNANAAAMEN1KMT2APDE4D | |
| SCHEMBL18227495 | 0.74 | LMNA (0.46) | LMNANAAAMEN1KMT2APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2022-05-05 | — | — | US | disclosed |
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2018-08-09 | — | — | US | disclosed |
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2018-08-09 | — | — | US | disclosed |
| WO-2016183150-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | LMNA 2909/4885NAAA 3636/4885MEN1 4868/4885 |
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | LMNA 2368/4885NAAA 3480/4885MEN1 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.